STOCK TITAN

[Form 4] Radius Recycling, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Lifecore Biomedical (LFCR) – CFO insider equity transaction

On 07/08/2025, Chief Financial Officer Ryan D. Lake reported the vesting of 75,000 performance-based restricted stock units (RSUs). The units converted into common shares (Form 4, code M), lifting his direct holdings to 392,429 shares.

To satisfy statutory tax withholding, the issuer automatically withheld 32,806 shares at $8.19 per share (code F). After this offset, Lake’s direct ownership stands at 359,623 shares, a net increase of roughly 42 k shares versus the pre-transaction level. He also retains 600,000 unexercised performance-based RSUs that continue to vest through 09/03/2029 once additional share-price milestones are achieved.

The filing reflects routine equity-compensation settlement rather than an open-market purchase or discretionary sale. Nonetheless, the additional shares keep the CFO’s incentives aligned with shareholder value creation.

Lifecore Biomedical (LFCR) – Transazione azionaria interna del CFO

Il 08/07/2025, il Chief Financial Officer Ryan D. Lake ha segnalato il maturare di 75.000 unità azionarie vincolate basate sulle performance (RSU). Le unità si sono convertite in azioni ordinarie (Modulo 4, codice M), portando la sua partecipazione diretta a 392.429 azioni.

Per adempiere alla ritenuta fiscale obbligatoria, l'emittente ha trattenuto automaticamente 32.806 azioni a $8,19 per azione (codice F). Dopo questa compensazione, la proprietà diretta di Lake è pari a 359.623 azioni, con un aumento netto di circa 42.000 azioni rispetto al livello precedente alla transazione. Mantiene inoltre 600.000 RSU basate sulle performance non ancora esercitate che continueranno a maturare fino al 03/09/2029 al raggiungimento di ulteriori obiettivi di prezzo delle azioni.

La comunicazione riflette una normale liquidazione di compensi azionari e non un acquisto sul mercato aperto o una vendita discrezionale. Tuttavia, le azioni aggiuntive mantengono gli incentivi del CFO allineati alla creazione di valore per gli azionisti.

Lifecore Biomedical (LFCR) – Transacción interna de acciones del CFO

El 08/07/2025, el Director Financiero Ryan D. Lake reportó la consolidación de 75,000 unidades restringidas basadas en desempeño (RSUs). Las unidades se convirtieron en acciones ordinarias (Formulario 4, código M), elevando su participación directa a 392,429 acciones.

Para cumplir con la retención fiscal obligatoria, el emisor retuvo automáticamente 32,806 acciones a $8.19 por acción (código F). Tras esta compensación, la propiedad directa de Lake es de 359,623 acciones, un aumento neto de aproximadamente 42,000 acciones respecto al nivel previo a la transacción. Además, conserva 600,000 RSUs basadas en desempeño no ejercidas que seguirán consolidándose hasta el 03/09/2029 al alcanzar hitos adicionales del precio de la acción.

El informe refleja una liquidación rutinaria de compensación en acciones, no una compra en mercado abierto ni una venta discrecional. No obstante, las acciones adicionales mantienen los incentivos del CFO alineados con la creación de valor para los accionistas.

Lifecore Biomedical (LFCR) – CFO 내부 주식 거래

2025년 7월 8일, 최고재무책임자(CFO) 라이언 D. 레이크75,000개의 성과 기반 제한 주식 단위(RSU)의 확정 사실을 보고했습니다. 이 단위들은 보통주로 전환되었으며(Form 4, 코드 M), 그의 직접 보유 주식 수는 392,429주로 증가했습니다.

법정 세금 원천징수를 위해 발행사는 자동으로 32,806주를 주당 $8.19에 원천징수했습니다(코드 F). 이 조정 후 레이크의 직접 보유 주식은 359,623주로, 거래 전보다 약 42,000주가 순증가했습니다. 또한 그는 추가 주가 목표 달성 시 2029년 9월 3일까지 계속 확정되는 600,000개의 미행사 성과 기반 RSU를 보유하고 있습니다.

이 신고는 공개 시장에서의 매수나 임의 매도가 아니라 일상적인 주식 보상 정산을 반영합니다. 그럼에도 불구하고 추가 주식은 CFO의 인센티브를 주주 가치 창출과 일치시키는 역할을 합니다.

Lifecore Biomedical (LFCR) – Transaction d’actions initiée par le CFO

Le 08/07/2025, le directeur financier Ryan D. Lake a déclaré la levée de 75 000 unités d’actions restreintes basées sur la performance (RSU). Ces unités ont été converties en actions ordinaires (Formulaire 4, code M), portant sa détention directe à 392 429 actions.

Pour satisfaire à la retenue fiscale obligatoire, l’émetteur a automatiquement prélevé 32 806 actions au prix de 8,19 $ par action (code F). Après cette compensation, la détention directe de Lake s’élève à 359 623 actions, soit une augmentation nette d’environ 42 000 actions par rapport au niveau avant la transaction. Il détient également 600 000 RSU basées sur la performance non exercées qui continueront à se libérer jusqu’au 03/09/2029, sous réserve de l’atteinte de nouveaux objectifs de cours.

Ce dépôt reflète un règlement courant de rémunération en actions, et non un achat sur le marché ouvert ni une vente discrétionnaire. Néanmoins, ces actions supplémentaires maintiennent l’alignement des incitations du CFO avec la création de valeur pour les actionnaires.

Lifecore Biomedical (LFCR) – Insider-Aktientransaktion des CFO

Am 08.07.2025 meldete der Chief Financial Officer Ryan D. Lake die Vesting von 75.000 leistungsabhängigen Restricted Stock Units (RSUs). Die Einheiten wurden in Stammaktien umgewandelt (Formular 4, Code M), wodurch sein direkter Bestand auf 392.429 Aktien anstieg.

Zur Erfüllung der gesetzlichen Steuerabzüge behielt der Emittent automatisch 32.806 Aktien zu je 8,19 $ ein (Code F). Nach diesem Ausgleich beträgt Lakes direkte Beteiligung 359.623 Aktien, eine Nettosteigerung von etwa 42.000 Aktien gegenüber dem Stand vor der Transaktion. Zudem hält er 600.000 nicht ausgeübte leistungsabhängige RSUs, die weiterhin bis zum 03.09.2029 vesten, sobald weitere Kursziele erreicht werden.

Die Meldung spiegelt eine routinemäßige Abwicklung der Aktienvergütung wider und keine Käufe am offenen Markt oder diskretionäre Verkäufe. Dennoch sorgen die zusätzlichen Aktien dafür, dass die Anreize des CFO mit der Wertschaffung für die Aktionäre in Einklang bleiben.

Positive
  • CFO’s direct ownership rises by 42,194 shares, enhancing alignment with shareholders.
  • 600,000 performance-based RSUs remain outstanding, tying future compensation to share-price performance.
Negative
  • Shares were acquired via vesting, not open-market purchase, reducing the traditional bullish signal strength.
  • 32,806 shares were withheld for taxes, representing an immediate disposal rather than a long-term holding increase.

Insights

TL;DR: Vesting of 75 k RSUs; net 42 k share increase; compensation-driven, not open-market, so largely neutral for LFCR.

The Form 4 shows a standard performance-based award converting into stock. Code M indicates automatic conversion, not a cash purchase, limiting its traditional ‘bullish’ insider-buy signal. The simultaneous code F disposition is a tax-withholding mechanism, not a discretionary sale. Post-transaction, Lake still owns 359,623 shares and 600,000 unvested RSUs that hinge on future price milestones, providing continued performance alignment. From a governance standpoint, the event neither increases float materially nor signals management sentiment beyond compensation norms; therefore, it is neutral in market impact.

Lifecore Biomedical (LFCR) – Transazione azionaria interna del CFO

Il 08/07/2025, il Chief Financial Officer Ryan D. Lake ha segnalato il maturare di 75.000 unità azionarie vincolate basate sulle performance (RSU). Le unità si sono convertite in azioni ordinarie (Modulo 4, codice M), portando la sua partecipazione diretta a 392.429 azioni.

Per adempiere alla ritenuta fiscale obbligatoria, l'emittente ha trattenuto automaticamente 32.806 azioni a $8,19 per azione (codice F). Dopo questa compensazione, la proprietà diretta di Lake è pari a 359.623 azioni, con un aumento netto di circa 42.000 azioni rispetto al livello precedente alla transazione. Mantiene inoltre 600.000 RSU basate sulle performance non ancora esercitate che continueranno a maturare fino al 03/09/2029 al raggiungimento di ulteriori obiettivi di prezzo delle azioni.

La comunicazione riflette una normale liquidazione di compensi azionari e non un acquisto sul mercato aperto o una vendita discrezionale. Tuttavia, le azioni aggiuntive mantengono gli incentivi del CFO allineati alla creazione di valore per gli azionisti.

Lifecore Biomedical (LFCR) – Transacción interna de acciones del CFO

El 08/07/2025, el Director Financiero Ryan D. Lake reportó la consolidación de 75,000 unidades restringidas basadas en desempeño (RSUs). Las unidades se convirtieron en acciones ordinarias (Formulario 4, código M), elevando su participación directa a 392,429 acciones.

Para cumplir con la retención fiscal obligatoria, el emisor retuvo automáticamente 32,806 acciones a $8.19 por acción (código F). Tras esta compensación, la propiedad directa de Lake es de 359,623 acciones, un aumento neto de aproximadamente 42,000 acciones respecto al nivel previo a la transacción. Además, conserva 600,000 RSUs basadas en desempeño no ejercidas que seguirán consolidándose hasta el 03/09/2029 al alcanzar hitos adicionales del precio de la acción.

El informe refleja una liquidación rutinaria de compensación en acciones, no una compra en mercado abierto ni una venta discrecional. No obstante, las acciones adicionales mantienen los incentivos del CFO alineados con la creación de valor para los accionistas.

Lifecore Biomedical (LFCR) – CFO 내부 주식 거래

2025년 7월 8일, 최고재무책임자(CFO) 라이언 D. 레이크75,000개의 성과 기반 제한 주식 단위(RSU)의 확정 사실을 보고했습니다. 이 단위들은 보통주로 전환되었으며(Form 4, 코드 M), 그의 직접 보유 주식 수는 392,429주로 증가했습니다.

법정 세금 원천징수를 위해 발행사는 자동으로 32,806주를 주당 $8.19에 원천징수했습니다(코드 F). 이 조정 후 레이크의 직접 보유 주식은 359,623주로, 거래 전보다 약 42,000주가 순증가했습니다. 또한 그는 추가 주가 목표 달성 시 2029년 9월 3일까지 계속 확정되는 600,000개의 미행사 성과 기반 RSU를 보유하고 있습니다.

이 신고는 공개 시장에서의 매수나 임의 매도가 아니라 일상적인 주식 보상 정산을 반영합니다. 그럼에도 불구하고 추가 주식은 CFO의 인센티브를 주주 가치 창출과 일치시키는 역할을 합니다.

Lifecore Biomedical (LFCR) – Transaction d’actions initiée par le CFO

Le 08/07/2025, le directeur financier Ryan D. Lake a déclaré la levée de 75 000 unités d’actions restreintes basées sur la performance (RSU). Ces unités ont été converties en actions ordinaires (Formulaire 4, code M), portant sa détention directe à 392 429 actions.

Pour satisfaire à la retenue fiscale obligatoire, l’émetteur a automatiquement prélevé 32 806 actions au prix de 8,19 $ par action (code F). Après cette compensation, la détention directe de Lake s’élève à 359 623 actions, soit une augmentation nette d’environ 42 000 actions par rapport au niveau avant la transaction. Il détient également 600 000 RSU basées sur la performance non exercées qui continueront à se libérer jusqu’au 03/09/2029, sous réserve de l’atteinte de nouveaux objectifs de cours.

Ce dépôt reflète un règlement courant de rémunération en actions, et non un achat sur le marché ouvert ni une vente discrétionnaire. Néanmoins, ces actions supplémentaires maintiennent l’alignement des incitations du CFO avec la création de valeur pour les actionnaires.

Lifecore Biomedical (LFCR) – Insider-Aktientransaktion des CFO

Am 08.07.2025 meldete der Chief Financial Officer Ryan D. Lake die Vesting von 75.000 leistungsabhängigen Restricted Stock Units (RSUs). Die Einheiten wurden in Stammaktien umgewandelt (Formular 4, Code M), wodurch sein direkter Bestand auf 392.429 Aktien anstieg.

Zur Erfüllung der gesetzlichen Steuerabzüge behielt der Emittent automatisch 32.806 Aktien zu je 8,19 $ ein (Code F). Nach diesem Ausgleich beträgt Lakes direkte Beteiligung 359.623 Aktien, eine Nettosteigerung von etwa 42.000 Aktien gegenüber dem Stand vor der Transaktion. Zudem hält er 600.000 nicht ausgeübte leistungsabhängige RSUs, die weiterhin bis zum 03.09.2029 vesten, sobald weitere Kursziele erreicht werden.

Die Meldung spiegelt eine routinemäßige Abwicklung der Aktienvergütung wider und keine Käufe am offenen Markt oder diskretionäre Verkäufe. Dennoch sorgen die zusätzlichen Aktien dafür, dass die Anreize des CFO mit der Wertschaffung für die Aktionäre in Einklang bleiben.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
X
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Gregorio Mauro

(Last) (First) (Middle)
222 SW COLUMBIA ST
SUITE 1150

(Street)
PORTLAND OR 97201

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
RADIUS RECYCLING, INC. [ RDUS ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
07/10/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Class A Common Stock 07/10/2025 D(1) 11,096.679(1)(2) D $30(1)(2) 0 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. On July 10, 2025, Radius Recycling, Inc. (the "Issuer") completed the previously announced transaction with Toyota Tsusho America, Inc. ("Parent"), and TAI Merger Corporation ("Merger Sub"), pursuant to the Agreement and Plan of Merger dated as of March 13, 2025 (the "Merger Agreement"), whereby Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer continuing as the surviving corporation in the Merger as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, each share of Issuer Class A common stock ("Class A Common Stock") and Issuer Class B common stock ("Class B Common Stock" and together with Class A Common Stock, "Common Stock") that was issued and outstanding immediately prior to the Effective Time (as defined in the Merger Agreement) (other than certain properly dissenting shares) was converted into the right to receive $30.00 in cash (the "Merger Consideration"), without interest, and less applicable withholding taxes.
2. Includes 9,607 unvested Company DSU Awards (as defined in the Merger Agreement). Pursuant to the Merger Agreement, as of the Effective Time, each Company DSU Award that was outstanding immediately prior to the Effective Time became immediately vested and was cancelled and converted into the right to receive an amount in cash equal to the sum of (x) the product of (A) the Merger Consideration, multiplied by (B) the total number of shares of Common Stock subject to such Company DSU Award, plus (y) any accrued and unpaid dividends or dividend equivalent rights corresponding to such Company DSU Award.
/s/ Joseph J. Bradley, Attorney-in-Fact 07/10/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many LFCR shares did CFO Ryan Lake acquire on 07/08/2025?

He received 75,000 shares upon vesting of performance-based RSUs.

What is Ryan Lake’s current direct ownership in Lifecore Biomedical?

After the transaction, he holds 359,623 common shares directly.

Why were 32,806 LFCR shares disposed of in the filing?

They were automatically withheld to cover tax obligations related to the RSU vesting.

What does the 600,000 figure in the derivative table represent?

It is the remaining unvested performance-based RSUs that can convert to shares if price milestones are met by 09/03/2029.

Does this Form 4 signal an open-market insider purchase?

No. The code M transaction was a compensation-related vesting, not an open-market buy.
Radius Recycling Inc

NASDAQ:RDUS

RDUS Rankings

RDUS Latest News

RDUS Latest SEC Filings

RDUS Stock Data

839.54M
28.06M
6.56%
84.95%
2.14%
Steel
Wholesale-misc Durable Goods
Link
United States
PORTLAND